2f9v: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
[[Image:2f9v. | {{Seed}} | ||
[[Image:2f9v.png|left|200px]] | |||
<!-- | <!-- | ||
Line 9: | Line 10: | ||
{{STRUCTURE_2f9v| PDB=2f9v | SCENE= }} | {{STRUCTURE_2f9v| PDB=2f9v | SCENE= }} | ||
===HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with P1 and P2 cyclopropylalannines=== | |||
<!-- | |||
The line below this paragraph, {{ABSTRACT_PUBMED_16387495}}, adds the Publication Abstract to the page | |||
(as it appears on PubMed at http://www.pubmed.gov), where 16387495 is the PubMed ID number. | |||
--> | |||
{{ABSTRACT_PUBMED_16387495}} | |||
==About this Structure== | ==About this Structure== | ||
Line 20: | Line 24: | ||
==Reference== | ==Reference== | ||
Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity., Bogen SL, Ruan S, Liu R, Agrawal S, Pichardo J, Prongay A, Baroudy B, Saksena AK, Girijavallabhan V, Njoroge FG, Bioorg Med Chem Lett. 2006 Mar 15;16(6):1621-7. Epub 2006 Jan 4. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16387495 16387495] | Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity., Bogen SL, Ruan S, Liu R, Agrawal S, Pichardo J, Prongay A, Baroudy B, Saksena AK, Girijavallabhan V, Njoroge FG, Bioorg Med Chem Lett. 2006 Mar 15;16(6):1621-7. Epub 2006 Jan 4. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16387495 16387495] | ||
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide., Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA, Cell. 1996 Oct 18;87(2):343-55. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/8861917 8861917] | |||
Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency., Bogen S, Saksena AK, Arasappan A, Gu H, Njoroge FG, Girijavallabhan V, Pichardo J, Butkiewicz N, Prongay A, Madison V, Bioorg Med Chem Lett. 2005 Oct 15;15(20):4515-9. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16112862 16112862] | |||
Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design., Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J, J Med Chem. 2005 Aug 11;48(16):5088-91. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16078825 16078825] | |||
Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity., Chen KX, Njoroge FG, Vibulbhan B, Prongay A, Pichardo J, Madison V, Buevich A, Chan TM, Angew Chem Int Ed Engl. 2005 Nov 4;44(43):7024-8. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/16211639 16211639] | |||
Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex., Arasappan A, Njoroge FG, Parekh TN, Yang X, Pichardo J, Butkiewicz N, Prongay A, Yao N, Girijavallabhan V, Bioorg Med Chem Lett. 2004 Dec 6;14(23):5751-5. PMID:[http://www.ncbi.nlm.nih.gov/pubmed/15501035 15501035] | |||
[[Category: Hepatitis c virus]] | [[Category: Hepatitis c virus]] | ||
[[Category: Protein complex]] | [[Category: Protein complex]] | ||
Line 36: | Line 50: | ||
[[Category: Ketoamide inhibitor]] | [[Category: Ketoamide inhibitor]] | ||
[[Category: Ns3 protease]] | [[Category: Ns3 protease]] | ||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on | |||
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 20:39:28 2008'' |
Revision as of 20:39, 28 July 2008
HCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with P1 and P2 cyclopropylalanninesHCV NS3 protease domain with NS4a peptide and a ketoamide inhibitor with P1 and P2 cyclopropylalannines
Template:ABSTRACT PUBMED 16387495
About this StructureAbout this Structure
2F9V is a Protein complex structure of sequences from Hepatitis c virus. Full crystallographic information is available from OCA.
ReferenceReference
Depeptidization efforts on P3-P2' alpha-ketoamide inhibitors of HCV NS3-4A serine protease: effect on HCV replicon activity., Bogen SL, Ruan S, Liu R, Agrawal S, Pichardo J, Prongay A, Baroudy B, Saksena AK, Girijavallabhan V, Njoroge FG, Bioorg Med Chem Lett. 2006 Mar 15;16(6):1621-7. Epub 2006 Jan 4. PMID:16387495
Crystal structure of the hepatitis C virus NS3 protease domain complexed with a synthetic NS4A cofactor peptide., Kim JL, Morgenstern KA, Lin C, Fox T, Dwyer MD, Landro JA, Chambers SP, Markland W, Lepre CA, O'Malley ET, Harbeson SL, Rice CM, Murcko MA, Caron PR, Thomson JA, Cell. 1996 Oct 18;87(2):343-55. PMID:8861917
Hepatitis C virus NS3-4A serine protease inhibitors: use of a P2-P1 cyclopropyl alanine combination for improved potency., Bogen S, Saksena AK, Arasappan A, Gu H, Njoroge FG, Girijavallabhan V, Pichardo J, Butkiewicz N, Prongay A, Madison V, Bioorg Med Chem Lett. 2005 Oct 15;15(20):4515-9. PMID:16112862
Design and synthesis of depeptidized macrocyclic inhibitors of hepatitis C NS3-4A protease using structure-based drug design., Venkatraman S, Njoroge FG, Girijavallabhan VM, Madison VS, Yao NH, Prongay AJ, Butkiewicz N, Pichardo J, J Med Chem. 2005 Aug 11;48(16):5088-91. PMID:16078825
Proline-based macrocyclic inhibitors of the hepatitis C virus: stereoselective synthesis and biological activity., Chen KX, Njoroge FG, Vibulbhan B, Prongay A, Pichardo J, Madison V, Buevich A, Chan TM, Angew Chem Int Ed Engl. 2005 Nov 4;44(43):7024-8. PMID:16211639
Novel 2-oxoimidazolidine-4-carboxylic acid derivatives as hepatitis C virus NS3-4A serine protease inhibitors: synthesis, activity, and X-ray crystal structure of an enzyme inhibitor complex., Arasappan A, Njoroge FG, Parekh TN, Yang X, Pichardo J, Butkiewicz N, Prongay A, Yao N, Girijavallabhan V, Bioorg Med Chem Lett. 2004 Dec 6;14(23):5751-5. PMID:15501035
Page seeded by OCA on Mon Jul 28 20:39:28 2008